Widely used:Recently Viewed
Clear All
$44 Mln
--
1.97
--
0
--
--
--
--
-410285833
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Atara Biotherapeutics (ATRA)
| -38.87 | -17.21 | -5.31 | -77.76 | -73.89 | -53.25 | -- |
|
BSE Sensex
| 13.00 | 0.56 | 2.05 | 23.70 | 11.01 | 16.81 | 12.01 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Atara Biotherapeutics (ATRA)
| -84.36 | -79.19 | -19.71 | 19.19 | -52.59 | 91.25 | 27.46 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$43.80 Mln
$62.39 Mln
$-69.80 Mln
$35.44 Mln
$89.83 Mln
High
$4.98 - 45.75
5,673,950
NASDAQ: ATRA
Thousand Oaks, CA
https://www.atarabio.com
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel... (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320 Read more
The total asset value of Atara Biotherapeutics Inc (ATRA) stood at $ 266 Mln as on 30-Jun-24
The share price of Atara Biotherapeutics Inc (ATRA) is $7.84 (NASDAQ) as of 08-Oct-2024 16:00 EDT. Atara Biotherapeutics Inc (ATRA) has given a return of -73.89% in the last 3 years.
Atara Biotherapeutics Inc (ATRA) has a market capitalisation of $ 44 Mln as on 08-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Atara Biotherapeutics Inc (ATRA) is 1.97 times as on 08-Oct-2024, a 37% discount to its peers’ median range of 3.14 times.
Since, TTM earnings of Atara Biotherapeutics Inc (ATRA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Atara Biotherapeutics Inc (ATRA) and enter the required number of quantities and click on buy to purchase the shares of Atara Biotherapeutics Inc (ATRA).
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320
The CEO & director of Dr. Pascal Touchon D.V.M.. is Atara Biotherapeutics Inc (ATRA), and CFO & Sr. VP is Dr. Anhco Nguyen Ph.D..
There is no promoter pledging in Atara Biotherapeutics Inc (ATRA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Atara Biotherapeutics Inc. (ATRA) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
-266.19
|
|
Net Margin(%)
|
-2902.01
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Atara Biotherapeutics Inc (ATRA) was $-70 Mln.
$0.12
